文献速递甲状腺与颈部外科

甲状腺叶切除与全甲状腺切除治疗伴淋巴结转移的中危甲状腺乳头状癌的比较

Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis.
PubMed 文献 · JAMA Surg · 2023-01-01

这项回顾性队列研究纳入946例单侧甲状腺乳头状癌伴同侧颈侧区淋巴结转移的成人患者,经倾向性评分匹配后比较甲状腺叶切除与全甲状腺切除的无复发生存率。结论提示若不行放射性碘消融,甲状腺叶切除可能是有效替代选择。

要点

  • 中危甲状腺乳头状癌伴淋巴结转移者,叶切除与全切的无复发生存率无显著差异。
  • 若计划不行放射性碘消融,甲状腺叶切除可作为有效替代方案。
  • 该结论基于倾向性评分匹配的回顾性队列,需前瞻性研究验证。

核心结论

  • 伴淋巴结转移的甲状腺乳头状癌患者,甲状腺叶切除与全甲状腺切除的无复发生存率相似。
  • 若不进行放射性碘消融,甲状腺叶切除可能是有效替代选择。

研究设计与样本

  • 回顾性队列研究,纳入2000年1月1日至2017年12月31日单中心收治的成人(18-75岁)单侧甲状腺乳头状癌伴同侧临床颈侧区淋巴结转移(cN1b)患者。
  • 排除淋巴结检出数少于20、原发肿瘤大于4 cm、 gross extrathyroidal extension、转移淋巴结大于3 cm及远处转移者。
  • 采用倾向性评分匹配比较甲状腺叶切除与全甲状腺切除患者,匹配因素包括治疗时期及年龄、性别、原发肿瘤大小、多灶性、 minor extrathyroidal extension、转移淋巴结数目和淋巴结比率。
  • 共946例患者纳入分析,匹配后每组265对。

主要发现

  • 匹配后中位随访时间:叶切除组60个月(范围9-150),全甲状腺切除组58个月(范围8-161)。
  • 叶切除组21例(7.9%)和全甲状腺切除组17例(6.4%)出现结构性复发。
  • 功效分析显示检测大于4.9%的无复发生存率差异有90%功效。

临床怎么用

  • 对于严格筛选的单侧甲状腺乳头状癌伴颈侧区淋巴结转移患者,可考虑甲状腺叶切除。
  • 若计划不行放射性碘消融,甲状腺叶切除可作为全甲状腺切除的替代选择。

局限性

  • 回顾性队列设计,存在选择偏倚可能。
  • 单中心研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Surgical treatment of patients with papillary thyroid cancer (PTC) by either lobectomy or total thyroidectomy (TT) has long been a topic of debate, especially for patients with intermediate-risk PTC. OBJECTIVE: To compare recurrence-free survival (RFS) for patients with PTC and lymph node metastasis after lobectomy vs TT. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included a review of patients with PTC treated from January 1, 2000, to December 31, 2017. Propensity score matching (PSM) was performed between patients treated with lobectomy and TT. This study involved a single institute in a cancer referral center. Enrolled were adult patients (aged 18-75 years) with unilateral PTC and ipsilateral clinical lateral neck metastasis (cN1b). Patients with the following characteristics were excluded: a lymph node yield less than 20, primary tumor size greater than 4 cm, gross extrathyroidal extension, metastatic lymph node size greater than 3 cm, and distant metastasis. Data analysis was performed from April 1 to April 30, 2022. EXPOSURES: Lobectomy and TT. MAIN OUTCOMES AND MEASURES: The primary outcome was the association between extent of surgery and RFS, assessed using Cox proportional hazards regression models. RESULTS: A total of 946 patients with PTC (mean [SD] age, 37.0 [12.1] years, 630 female individuals [66.6%]) were analyzed. Lobectomy (624 [66.0%]) was negatively correlated with the frequencies of older age (≥65 years, 17 [2.7%]), female sex (393 [63.0%]), multifocality (132 [21.2%]), minor extrathyroidal extension (259 [41.5%]), number of metastatic lymph nodes (median [range], 9 [6-14] nodes), and radioactive iodine ablation (0). After PSM with treatment period and potential prognostic factors (age, sex, primary tumor size, multifocality, minor extrathyroidal extension, number of lymph node metastases and lymph node ratio), 265 pairs of patients were available for analysis. After a median (range) follow-up of 60 (9-150) months in the lobectomy group and 58 (8-161) months in the TT group, 21 (7.9%) and 17 (6.4%) structural recurrences were identified in the lobectomy and TT groups, respectively. Lobectomy was not associated with significantly compromised 5-year RFS rate (lobectomy, 92.3% vs TT, 93.7%; adjusted hazard ratio, 1.10; 95% CI, 0.58-2.11; P = .77). Power analysis indicated that the test had 90% power to detect a more than 4.9% RFS difference. No significant difference in RFS was observed between patients treated with TT and radioactive iodine ablation (n = 75) and their counterparts (adjusted hazard ratio, 0.59; 95% CI, 0.14-2.41; P = .46). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that patients with PTC and lymph node metastasis had a similar RFS after lobectomy vs those who had TT. If radioactive iodine ablation is not going to be performed, lobectomy may be an effective alternative option.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Xu S, Huang H, Huang Y, et al. Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis. JAMA Surg. 2023. PMID: 36449303. doi:10.1001/jamasurg.2022.5781

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。